Guo Kaidi, van den Beucken Twan
Department of Toxicogenomics, GROW - Research Institute for Oncology & Reproduction, Maastricht University, Maastricht, 6200, MD, The Netherlands.
Cell Biosci. 2024 Nov 2;14(1):134. doi: 10.1186/s13578-024-01317-2.
Drug-induced liver injury (DILI) refers to drug-mediated damage to the structure and function of the liver, ranging from mild elevation of liver enzymes to severe hepatic insufficiency, and in some cases, progressing to liver failure. The mechanisms and clinical symptoms of DILI are diverse due to the varying combination of drugs, making clinical treatment and prevention complex. DILI has significant public health implications and is the primary reason for post-marketing drug withdrawals. The search for reliable preclinical models and validated biomarkers to predict and investigate DILI can contribute to a more comprehensive understanding of adverse effects and drug safety. In this review, we examine the progress of research on DILI, enumerate in vitro models with potential benefits, and highlight cellular molecular perturbations that may serve as biomarkers. Additionally, we discuss omics approaches frequently used to gather comprehensive datasets on molecular events in response to drug exposure. Finally, three commonly used gene modulation techniques are described, highlighting their application in identifying causal relationships in DILI. Altogether, this review provides a thorough overview of ongoing work and approaches in the field of DILI.
药物性肝损伤(DILI)是指药物介导的肝脏结构和功能损害,范围从肝酶轻度升高到严重肝功能不全,在某些情况下,会进展为肝衰竭。由于药物组合各异,DILI的机制和临床症状多种多样,这使得临床治疗和预防变得复杂。DILI具有重大的公共卫生影响,是上市后药物撤市的主要原因。寻找可靠的临床前模型和经过验证的生物标志物来预测和研究DILI,有助于更全面地了解药物不良反应和药物安全性。在本综述中,我们考察了DILI的研究进展,列举了具有潜在益处的体外模型,并强调了可能作为生物标志物的细胞分子扰动。此外,我们还讨论了常用于收集药物暴露后分子事件综合数据集的组学方法。最后,描述了三种常用的基因调控技术,突出了它们在确定DILI因果关系中的应用。总之,本综述全面概述了DILI领域正在进行的工作和方法。